tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'FDA'

Nuvilex, Inc.’s Phase III Pancreatic Cancer Trials Could Address New Law’s Call for Progress

Nuvilex, Inc.’s Phase III Pancreatic Cancer Trials Could Address New Law’s Call for Progress

Written by ι Stock Market Media Group Staff — June 24, 2013

Nuvilex, Inc. (OTCQB: NVLX) has a great opportunity to demonstrate and showcase its encapsulation technology in its upcoming Phase III clinical trials for the treatment of late stage, inoperable pancreatic cancer.  There will be plenty of interested observers, and you can bet that those US Senators and Congressmen responsible for the Recalcitrant Cancer Research Act that was signed into law earlier this year, will be among them.

Nuvilex’s upcoming late stage ...

Read More →
0

Plandai Biotechnology, Inc. Product Proven to Decrease Healing Time of Sports Related Injuries

Plandai Biotechnology, Inc. Product Proven to Decrease Healing Time of Sports Related Injuries

Written by ι Stock Market Media Group Staff — May 21, 2013

In a series of articles to introduce Plandaí Biotechnology, Inc.’s (OTCQB: PLPL) three highly bioavailable products, the second of three introduces what could be the go-to solution for the common cold.  All of Plandaí’s extracts will be individually labeled and marketed under the Phytofare™ brand.

Much like its first product, Phytofare™ Catechin Extract, Plandaí’s Phytofare™ Limonoid Glycoside Complex will hit the market and offer the company’s customers a higher absorption rate than ...

Read More →
0

Nuvilex, Inc. and Celgene Corp. Can Both Replace Eli Lilly’s Cancer Drug Gemzar

Nuvilex, Inc. and Celgene Corp. Can Both Replace Eli Lilly’s Cancer Drug Gemzar

Written by ι Stock Market Media Group Staff — May 20, 2013

The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner’s treatment.  Two biotechnology companies are registering impressive data in each of their own pancreatic cancer trials, so impressive in fact, Eli Lilly & Co. (NYSE: LLY) is surely feeling its long time reign as the current standard single-drug treatment for the disease being threatened.  Nuvilex, Inc. (OTCQB: NVLX) and Celgene Corp. (NASDAQ: ...

Read More →
0

Plandaí Biotechnology, Inc. New Products to Hit the Market with Higher Absorption Rate

Plandaí Biotechnology, Inc. New Products to Hit the Market with Higher Absorption Rate

Written by ι Stock Market Media Group Staff — May 14, 2013

In a series of articles Stock Market Media Group, a research and content development investment relations firm, will lay out Plandaí Biotechnology, Inc.’s (OTCQB: PLPL) three new products all being individually labeled and branded under the Phytofare™ name.  In addition to the products, the patented extraction process the company will use to bring customers its healthy lineup of extracts will also be highlighted.  This installment will focus on the first of ...

Read More →
0
Page 4 of 4 1234
ContactUs.com